Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Abstract
Apolipoprotein E (ApoE) has been recently identified as a potential tumor-associated marker in ovarian cancer by serial analysis of gene expression. ApoE has long been known to play a key role in lipid transport, and its specific isoforms may participate in atherosclerogenesis. However, its role in human cancer is not known. In this study, apoE expression was frequently detected in ovarian serous carcinomas, the most common and lethal type of ovarian cancer. It was not detected in serous borderline tumors and normal ovarian surface epithelium. Inhibition of apoE expression using an apoE-specific siRNA led to G2 cell cycle arrest and apoptosis in an apoE-expressing ovarian cancer cell line, OVCAR3, but not in apoE-negative cell lines. Furthermore, the phenotype of apoE siRNA–treated OVCAR3 cells was reversed by expressing engineered mutant apoE with introduced silent mutations in the siRNA target sequence. Expression of apoE in nuclei was significantly associated with a better survival in patients who presented peritoneal effusion at the time of diagnosis (5-year follow-up, P = 0.004). This study suggests a new role of apoE in cancer as apoE expression is important for the proliferation and survival in apoE-expressing ovarian cancer cells.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mechanisms underlying the association between high apoE levels and increased cancer mortality could likely be due to apoE involvement in metastasis and angiogenesis.
“mechanisms underlying the association between high apoE levels and increased cancer mortality could likely be due to apoE involvement in metastasis and angiogenesis.49–56”
Cites
Apolipoprotein E and cognitive performance
Raber, J., Wong, D., Yu, G.-Q., Buttini, M., Mahley, R. W., Pitas, R. E., & Mucke, L. (2000) · Nature · doi:10.1038/35006165 · Cited by 237 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kemp, S. B., Carpenter, E. S., Steele, N. G., Donahue, K. L., Nwosu, Z. C., Pacheco, A., Velez-Delgado, A., Menjivar, R. E., Lima, F., The, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3929 · Cited by 197 · see citing works
Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation
Yancey, P. G., Blakemore, J., Ding, L., Fan, D., Overton, C. D., Zhang, Y., Linton, M. F., & Fazio, S. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.202051 · Cited by 168 · see citing works
Direct Transcriptional Effects of Apolipoprotein E
Theendakara, V., Peters-Libeu, C. A., Spilman, P., Poksay, K. S., Bredesen, D. E., & Rao, R. V. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3562-15.2016 · Cited by 152 · see citing works
Shafi, O. (2016) · BMC Neurology · doi:10.1186/s12883-016-0765-2 · Cited by 125 · see citing works
Ultrasonically triggered drug delivery: Breaking the barrier
Husseini, G. A., Pitt, W. G., & Martins, A. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.07.051 · Cited by 87 · see citing works
Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz402 · Cited by 86 · see citing works
- Authors
- Chen, Y.-C., Pohl, G., Wang, T.-L., Morin, P. J., Risberg, B., Kristensen, G. B., Yu, A., Davidson, B., & Shih, I.-M.
- Affiliations
- 1Pathology, Departments of
- Johns Hopkins University (US)
- National Institute on Aging (US)
- 4Pathology and
- University of Oslo (NO)
- Venue
- Cancer Research
- Published
- 2005-01-01
- Volume
- 65
- Issue
- 1
- Pages
- 331-337
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1889797874
- Cited by
- 155
- References
- 1
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 5 · 2014: 8 · 2013: 12 · 2012: 7
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-103937, R01CA103937)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- apolipoprotein E, ovarian cancer, serous carcinoma, cell proliferation, apoptosis, G2 cell cycle arrest, siRNA knockdown, patient survival, ascites, OVCAR-3 cells, nuclear localization
- MeSH terms
- Apolipoproteins E, Cell Cycle, Cell Division, Cell Survival, Female, Gene Expression Regulation, Humans, Mitosis, Ovarian Neoplasms, Survival Analysis, Gene Deletion, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review